Breast cancer resistance protein ( BCRP ) is a recently identified new member of the superfamily of ATP -binding cassette transporters. BCRP is a``half transporter'' that may homo -or heterodimerize to form an active transport complex. A considerable overexpression of BCRP was reported from various atypical multidrug -resistant tumor cell lines, in particular from those which were established by treatment with mitoxantrone. Thus, BCRP represents a very interesting candidate molecule for reversal of a drug -resistant phenotype. Six hammerhead ribozymes directed against the BCRP -encoding mRNA were designed and tested for their ability to cleave their target molecule. The anti -BCRP ribozymes were in vitro synthesized using bacteriophage T7 RNA polymerase and oligonucleotide primers whereby one primer contains a T7 RNA polymerase promoter sequence. BCRP -encoding substrate RNA molecules were created by a reverse transcription polymerase chain reaction using total RNA prepared from the atypical multidrug -resistant gastric carcinoma cell line EPG85 -257RNOV exhibiting a high BCRP mRNA expression level. One anti -BCRP ribozyme was found to show a very high endoribonucleolytic cleavage activity at physiologic pH and temperature. This ribozyme was characterized in a cell -free system with regard to its specific kinetic parameters using large target molecules.
T he simultaneous resistance of cancer cells to various antitumor agents, which are structurally and functionally unrelated, is a common phenomenon designated as multidrug resistance (MDR ). The multidrug -resistant phenotype is one of the major causes of failures of therapeutic treatment of human malignancies. Besides the classical MDR phenotype mediated by elevated activity of the ATP -binding cassette (ABC ) transporter P -glycoprotein ( P-gp) ( newsworthy overview in Ref. 1 ), alternative forms of multidrug -resistant tumor cells have been described. One term used to designate this phenomenon is atypical MDR. ABC transporters can act as energy-dependent drug efflux pumps. This transport activity results in decreased intracellular concentrations of antineoplastic agents.
Several ABC transporters can be involved in atypical forms of MDR, e.g., MDR protein 1 (MRP1, ABCC1; newsworthy overview in Ref.
2 ), MRP2 (cMOAT, ABCC2; newsworthy overview in Ref. 3 ), MRP3 ( MOAT-D, ABCC3), 4 or breast cancer resistance protein ( BCRP, MXR, ABCG2). 5 BCRP (newsworthy overview in Ref. 6 ) was found to be overexpressed in a variety of atypical multidrug -resistant human cancer cell lines, which were established by in vitro exposure either to mitoxantrone, topotecan, doxorubicin, or bisantrene. 7 BCRP is an approximately 72 -kDa ABC``half transporter'' of 655 amino acids and may homo -or heterodimerize to form an active transport complex. However, transfection experiments using the BCRP-encoding cDNA confer an atypical MDR phenotype to former drug -sensitive cancer cells. 6 Suppression of the expression of the BCRP -encoding gene is a potential therapeutical strategy to overcome the drug -resistant phenotype of cancer cells. Powerful techniques for this modulation are strategies based on the treatment of the tumor cells with antisense oligonucleotides or hammerhead ribozymes, whereby ribozymes have the advantage over antisense oligonucleotides that they destroy their target molecule due to their endoribonucleolytic activities. Hammerhead ribozymes can be designed to cleave a specific mRNA molecule at a defined position in trans, provided the target molecule contains a NUX motif, in which`N '' is any nucleotide ( nt ) and``X'' is A,C, or U. 8 Both techniques, antisense oligonucleotides and ribozymes, have been demonstrated to be useful in modulation of gene expression, including oncogenes 9,10 and drug resistance± associated genes. 11 ± 14 Thus, the application of the hammerhead ribozyme strategy for modulation of BCRP gene expression should allow the decrease of the BCRP -mediated drug efflux activity and may reverse the cell's drug sensitivity.
Here, we report the design and characterization of hammerhead ribozymes directed against the BCRP-specific mRNA. Of six hammerhead ribozymes examined, one was chosen to specifically cleave the BCRP-encoding mRNA molecule most efficiently. This hammerhead ribozyme was characterized concerning its specific kinetic parameters so that it could be proved that the ribozyme exhibits a high endoribonucleolytic cleavage activity.
MATERIALS AND METHODS

Design and synthesis of anti -BCRP hammerhead ribozymes
NUX motifs in the BCRP -encoding mRNA were estimated to be suitable hammerhead ribozyme targets, if these motifs were localized in nonbase -paired regions, e.g., hairpin loop structures. Therefore, a computer-based secondary structure analysis of the BCRP -encoding mRNA molecule was performed by application of the DNASIS 3.0 ( Hitachi, Yokohama, Japan ) and the mfold 3.0 ( Washington University, St. Louis, MO; E-mail address: http:/ /mfold2.wustl.edu / $mfold /rna / form1.cgi ) software. The BCRP mRNA sequence and the nucleotide ( nt ) positions were derived from human BCRP cDNA sequence (accession no. AF098951 ). 5 Nucleotide position + 1 is assigned to the A residue of the ATG translation start codon. Potential hammerhead ribozyme cleavage sites were selected at nt 5, nt 166, nt 1011, nt 1203, nt 1209, and nt 1400. These target sequences were not blocked by any secondary structure. Hammerhead ribozymes were named RzB1 ±RzB6. For each hammerhead ribozyme, an encoding sense ssDNA, 5
H -linked with a bacteriophage T7 RNA polymerase promoter sequence (sequences are shown in Table 1 ), as well as the homologous antisense ssDNA were synthesized on an oligonucleotide synthesizer. By application of these templates, the hammerhead ribozymes were synthesized by in vitro transcription as described previously. 15 
Truncated BCRP target transcripts
Two truncated BCRP -encoding DNA molecules were generated by polymerase chain reaction (PCR ) using total cDNA as template that was prepared from the BCRPoverexpressing, mitoxantrone -selected human gastric carcinoma cell line EPG85 -257RNOV. 16 In both cases, the forward sense primer was 5
H -linked with a bacteriophage T7 RNA polymerase promoter sequence. Oligonucleotide primers used for the amplification of substrate -1± encoding sequences were SUB1 -fw (nt À 79 to + 59 ), 5
H -TAA-TACGACTCACTATAGCCGAGCGCACGCATCCTGAG -3 H ( T7 promoter ± encoding sequence underlined ) and SUB1 -rev ( nt + 243to +5264 ), 5
H , yielding an expected product of 343 bp; for amplification of substrate -2± encoding sequences were SUB2 -fw ( nt + 965 to + 988 ), 5 H -TAATACGACT-CACTATAGCCAAGCAGGATAAGCCACTCATAG -3 H ( T7 promoter ±encoding sequence underlined ) and SUB2-rev ( nt + 1420 to + 1446 ), 5
H -CTGTTATCTGATTTAT-TACCCATGACG -3 H , yielding an expected product of 482 bp. To generate RNA -encoding DNA templates, the reaction mixture contained 100 ng total cDNA prepared from the cell line EPG85 -257RNOV, 0.2 mM of each oligonucleotide primer, 0.2 M of each dNTP, 50 mM KCl, 10 mM Tris ± HCl, pH 8.3, 1.5 mM MgCl 2 , 0.001% gelatin, and 1 unit of AmpliTaq ( Perkin Elmer ) in a final volume of 50 L. Cycling conditions were 90 seconds at 938C followed by 35 cycles consisting of 60 seconds at 938C, 90 seconds at 558C, and 90 seconds at 728C. The last cycle contained a 5 -minute extension step at 728C. Subsequently, the PCR products were purified with Sephadex G -50 columns. Both BCRPspecific RNA fragments were obtained by performing an in vitro transcription as described earlier. 15 
Ribozyme -mediated digestion of different BCRP substrates
To determine the anti -BCRP hammerhead ribozyme exhibiting the highest catalytic activity, cleavage reactions were performed according to the experimental procedure described previously, 15 but applying some modifications. The endoribonucleolytic reactions were performed in a final volume of 10 L containing 100 nM hammerhead ribozyme, 100 nM BCRP -specific transcript, 40 mM Tris ± HCl, pH 7.5, and 12 mM MgCl 2 at 378C. After 1 hour, the reactions were stopped by adding an equal volume of a stop buffer consisting of 8 M urea, 8.7% glycerin, 0.02% xylene cyanole, 0.02% bromephenole blue, and 0.02% orange G. Each sample was size -fractionated by polyacrylamide gel *Sequences and nt positions are derived from the human BCRP cDNA sequence ( accession no. AF098951 ). 5 The nt position + 1 is assigned to the A residue of the ATG translation start codon. The cleavage site following the NUX motif ( italicized ) is indicated by an arrow. The adjacent nucleotides correspond with the positions À 8 and + 6 relative to the cleaving triplet.
yCatalytic activity was determined as described in Materials and Methods. The cleavage reaction was performed for 1 hour at 378C using equimolar proportions of ribozyme and substrate. Substrate and cleaving products were identified by autoradiography. The endoribonucleolytic activity was determined according to the amount of scanned and counted cleaving product. The in vitro cleavage activities are indicated: ( À ) no acidity ( no detectable formation of cleavage products ); ( + ) weak activity ( formation of < 20% of cleavage products ); ( + + ) moderate activity ( formation of 21 ± 50% of cleavage products ); ( + + + ) high activity (formation of 51 ± 65% of cleavage activity ); ( + + + + ) very high activity ( formation of > 66% of cleavage products ). H -cleavage products were quantified to determine the extent of cleavage using the BioRad molecular analyst software package ( BioRad, Hercules, CA ). As a result of this procedure, RzB1 was identified as being the anti -BCRP ribozyme exhibiting the highest catalytic activity. Accordingly, all subsequent in vitro cleavage assays were performed with RzB1 and substrate -1 as a target to characterize RzB1 in detail.
Turnover kinetics
The value of the initial velocity (v ini ) of the RzB1 -catalyzed cleavage reaction was determined following the experimental procedure described previously 15 using some modifications. Additionally, the value of the observed cleavage constant k obs was determined. The catalytic reactions were started by adding 25 nM 32 P -labeled substrate -1 RNA to the reaction mix containing 125 nM 32 P -labeled RzB1 RNA, 40 mM Tris ±HCl, pH 7.5, and 12 mM MgCl 2 at 378C. All experiments were performed in a minimum of three times. Substrate:product ratios were estimated following PAGE, autoradiography, and densitometric evaluation using the BioRad molecular analyst software. The value for the initial velocity of RzB1 was calculated from the ascent of the graph in the product ±time diagram. The linear range of this graph was assessed by determination of the highest correlation coefficient obtained by the calculation of different linear regression curves using various breakpoints.
The experimental determination of the value of reaction parameter k cat / k m was carried out as described earlier. 15 Briefly, 40 nM target RNA was incubated with increasing concentrations of RzB1 (0 ±400 nM ) for 15 minutes at 378C. The reaction was started by adding the ribozyme RzB1 to the reaction mix containing substrate -1, 40 mM Tris ±HCl, pH 7.5, and 12 mM MgCl 2 . All experiments were performed at least in triplicate and analyzed as described above. To compare the RzB1 -specific value of k cat / k m with those given in the literature assessed by different approaches, k cat / k m was determined using two alternative calculations. The first method, given by Heidenreich and Eckstein, 17 relies on the accepted supposition that the digestion of the first 30% of the target molecules follows a linear curve, and based on that the whole amount of given substrate is cleavable. Under these circumstances, the k cat /k m value corresponds to the ascent of the linear beginning of the graph. The linear range of the graph was assessed as described above. In this calculation, the percentage of uncleaved substrate ( S u ) for each reaction time ( t) is plotted against the ribozyme concentration [ ribozyme ]. P t is the amount of cleavage products at time (t ):
The second determination of k cat /k m follows the equation given by Hendry et al: 18 P t P I À P e 18 The negative natural logarithm of the amount of formed cleavage products ( P t ) was plotted against the concentrations of the ribozyme. The value of k cat / k m = 55,000 6550 M À 1 s À 1 corresponds to the ascent of the apparent linear beginning of the curves ( small inserted figure ) . All experiments were performed at least in triplicate. KOWALSKI, WICHERT, HOLM, ET AL: BCRP RIBOZYME which is actually cleaved after a considerable space of time ( here 1 hour; described as t =I ). P t and t are the same as above, P I is the amount of cleavage products at that point of time t =I when the reaction rate was constant, and P is the difference between the percentage of cleavage products at t =I and t =0.
Due to the comparability of the kinetic data, the observed cleavage constant k obs was determined by two methods. ( i) The k obs value was assessed according to Heidenreich et al: 19 k obs À ln S u t whereby the reaction constant k obs equals the negative natural logarithm of the uncleaved substrate (S u ) divided by the reaction time t. This approach does not consider the efficiency of the cleavage reaction.
( ii ) The value of k obs was calculated by the improved approach given by Hendry et al: 18 P t P I À e Àk obs t P where P t is the amount of formed product at time t, P I is the amount of product at t= I, and P is the difference between the percentage of product at t= I and t =0. This approach takes into consideration that the ribozyme -mediated cleavage reaction is not complete.
RESULTS
Truncated BCRP substrate -specific oligonucleotide primers, 5 H -linked with bacteriophage T7 promoter sequences, were successfully applied for PCR -based DNA template synthesis. These templates, encoding BCRP substrate RNA molecules, were suitable for direct in vitro transcription without any cloning procedure. Corresponding results were obtained for bacteriophage T7 promoter sequence containing synthetic DNA molecules, which encoded anti -BCRP hammerhead ribozymes RzB1 ± RzB6.
Six different anti -BCRP hammerhead ribozymes with asymmetric 10-nt 5 H -antisense arms and 6 -nt 3 H -antisense arms were constructed according to the method of Haseloff and Gerlach. 20 These catalytic RNA molecules were tested in a cell-free assay for their ability to cleave in vitro transcribed truncated fragments of the BCRP -encoding mRNA. The used BCRP substrate fragments consisted of 343 -nt ( substrate -1) and 482 -nt (substrate -2 ). Five of six anti -BCRP hammerhead ribozymes were able to cleave truncated fragments of the BCRP -encoding mRNA at physiologic pH and temperature, and at equimolar concentrations of anti -BCRP hammerhead ribozymes and substrate RNA molecules in the reaction mixture (Fig 1;  Table 2 ). It could be demonstrated that hammerhead ribozyme RzB1 ( Fig 2) cleaved the BCRP -encoding mRNA fragment much more efficiently than the other anti -BCRP ribozymes examined (Fig 1; Table 2 ). The remaining ribozyme RzB6 tested showed no endoribonucleolytic activity. Therefore, anti -BCRP ribozyme RzB1 was selected for further examinations and characterized more in detail.
The ribozyme was examined as regards its capacity to cleave its RNA target sequence depending on time (Fig 3 ) and substrate:ribozyme ratio (Fig 4) . The amounts of ribozyme -catalyzed appearance of 5 H -and 3 H -cleavage products were measured when the turnover rate of the reaction became constant. As demonstrated in Figures 5 and  6 , this value, P I , was typically in the region of 0.5, i.e., $50% of the substrate was cleaved at the end of the ribozyme -catalyzed reaction. The value of the initial velocity of the ribozyme RzB1 -catalyzed RNA cleavage reaction was calculated as follows: v ini =2.21 0.5 fmol s À 1 ( Fig 6) . According to the equation of Hendry et al, 18 the value of the reaction parameter k cat /k m of RzB1 was Figure 9 . Experimental determination of the observed reaction constants k obs of the hammerhead ribozyme RzB1 according to Hendry et al. 18 The values of k obs correspond to the ascent of the apparent linear beginning of the curves ( small inserted figures ). All experiments were performed at least in triplicate. The value of k obs was calculated to be k obs = 2.675Â10 À 2 0.6Â10
. Figure 10 . Determination of the cleavage constant k obs of the anti -BCRP ribozyme RzB1 according to Heidenreich et al. 19 The values of k obs correspond to the ascent of the apparent linear beginning of the curves ( small inserted figures ). All experiments were performed at least in triplicate. The value of k obs was calculated to be k obs = 1.168Â10
Cancer Gene Therapy, Vol 8, No 3, 2001 determined as k cat / k m =55,000 6550 M À 1 s À 1 (Fig 7) and as k cat /k m = 24,180 3770 M À 1 s À 1 , applying the calculation method suggested by Heidenreich and Eckstein 17 ( Fig  8 ) . The value of the cleavage constant k obs of the anti -BCRP hammerhead ribozyme was calculated as k obs = 2.675Â10 À 2 0.6Â10 À 2 s À 1 (Fig 9 ) according to Hendry et al, 18 and as k obs =1.168Â10 À 2 0.3Â10 À 2 s À 1 ( Fig 10) using the equation developed by Heidenreich et al. 19 For comparison, the values of v ini , k cat /k m , and k obs for RzB1 are presented in Table 3 compared to those values that were determined using alternative hammerhead ribozymes.
DISCUSSION
The successful application of RNA sequence -specific hammerhead ribozymes to cleave any target molecule is, in principle, possible, if the target RNA contains a NUX motif. Thus, hammerhead ribozymes have a considerable potential to specifically modulate the expression of functional important cancer-associated genes. As example, the successful design of endoribonucleolytic active hammerhead ribozymes was reported for oncogenes such as cfos, 10 H-ras, 21 or c-myc. 22 In addition, hammerhead ribozymes were constructed for the specific cleavage of antineoplastic drug resistance ±associated factors, such as the ABC transporter P -gp, 12,13 dihydrofolate reductase, 23 or the vault component LRP. 14 On the other side, hammerhead ribozymes directed against alternative drug resistance ±mediating ABC transporters have not been successfully designed. Thus, a hammerhead ribozyme directed against the ABC transporter molecule BCRP, which is considerably overexpressed in various atypical multidrug -resistant tumor cell lines, 6 might be an excellent new candidate for modulating resistance against anticancer agents. It might be suitable both as a new laboratory tool for investigations concerning the detailed characterization of the role of BCRP in MDR as well as a potential ribozyme of therapeutic relevance. Hitherto, it was not possible to predict whether a given hammerhead ribozyme will show endoribonucleolytic activity or how efficient a catalyzed reaction of a hammerhead ribozyme will be. These problems can occur because various potential ribozyme recognition motifs are not accessible for the hammerhead ribozymes due to secondary structures of the target molecule. 24 Therefore, the optimal target sites for hammerhead ribozymes have to be determined empirically. However, our own experiences 13,15,25 ± 28 demonstrated that ribozyme construction following computer-based secondary structure analyses of the target molecules led to high -activity hammerhead ribozymes. The hammerhead ribozymes' target sites were chosen to be not within intrastrand base -pairing structures, and therefore may be accessible for hybridization and endoribonucleolytic cleavage. The experimental data demonstrated that a secondary structure analysis of the target mRNA provides more information concerning the accessibility of a putative ribozyme cleavage site. However, the in silico approach is suitable to support the ribozyme design, but for prediction of the cleavage efficiency the experimental investigation cannot be replaced.
Additional difficulties in ribozyme construction arise from the observation that the cleavage activity of ribozymes alters depending on the substrate's length. It was reported that a decrease ( up to 1000 -fold ) in catalytic activity can occur when longer substrate molecules are used ( 60 ±954 nt ). 17, 24 These larger RNA molecules can form complex secondary and tertiary structures that can mask the sequence motifs necessary for successful ribozyme hybridization. A possible strategy to prevent the influence of this phenomenon is the use of large RNA substrate molecules like it was chosen for the characterization of the anti -BCRP hammerhead ribozymes. It is assumed that the rate -limiting step of a ribozyme -catalyzed cleavage reaction is the recognition of the ribozyme target sequence. In addition, tertiary interactions can slow down product release and interfere with turnover. For these reasons, there are only few reports of hammerhead ribozymes exhibiting a high catalytic cleavage activity using long RNA substrate molecules. 15, 25, 28, 29 The analysis of the kinetic parameters of the anti -BCRP hammerhead ribozyme RzB1 indicates a very high endoribonucleolytic cleavage activity, compared with the kinetic values of other hammerhead ribozymes ( Table 3 ) . The use of hammerhead ribozymes directed against specific RNA sequences has been proposed as being a convenient tool for analyzing gene expression to modulate the malignancy of cancer or to modulate antineoplastic drug resistance. Our data suggest that the anti -BCRP hammerhead ribozyme RzB1 provides a potential help in cancer research and may serve as potential reversal agent of an atypical MDR phenotype when used in cancer gene therapy. This study was carried out in a cell -free system, and the catalytic cleavage activity of RzB1 has to be evaluated in drug -resistant tumor cells. However, these experiments are currently performed to demonstrate the catalytic effects of RzB1 in tumor cells.
